Experience with corneal collagen cross-linking finds new indication, safety criteria

Article

Increasing clinical experience with corneal collagen cross-linking using combined topical riboflavin application and ultraviolet-A (UVA) irradiation indicates this simple, nonsurgical intervention may be an effective treatment for keratoconus and iatrogenic keratectasia. However, its safety may depend on respecting a minimum corneal thickness threshold of 400 microns as a criterion for candidate selection, said Theo Seiler, MD, at the World Ophthalmology Congress.

Increasing clinical experience with corneal collagen cross-linking using combined topical riboflavin application and ultraviolet-A (UVA) irradiation indicates this simple, nonsurgical intervention may be an effective treatment for keratoconus and iatrogenic keratectasia. However, its safety may depend on respecting a minimum corneal thickness threshold of 400 microns as a criterion for candidate selection, said Theo Seiler, MD, at the World Ophthalmology Congress.

Dr. Seiler of the Institute for Refractive and Ophthalmic Surgery, Switzerland, explained Wednesday that the procedure aims to increase the stiffness of the cornea and its mechanical and biochemical resistance by inducing additional chemical bonds within the connective tissue. Initial preclinical experiments in which animal eyes underwent corneal abrasion, followed by 30 minutes of application of 0.1% riboflavin and irradiation with a UVA light source (365-nm, 3 mW/cm2) demonstrated that corneal biomechanical strength increased 1.5-fold.

The technique was first performed clinically in patients with keratoconus, and those studies showed it could convert progressive disease into forme fruste keratoconus without causing any complications or evidence of toxicity to the cornea, lens or iris. More recent experience in eyes with iatrogenic keratectasia has also produced exciting results, as the procedure was associated with a reduction in keratometry readings rather than just stabilization.

However, in an eye with iatrogenic kerectasis, an adverse endothelial reaction occurred as the first complication of the cross-linking procedure. That experience led to further research on keratocyte cytotoxicity of the riboflavin/UVA treatment and the recommendation for the corneal thickness rule.

"Studies in cell cultures and animal eyes show there is a very sharp endothelial damage threshold for this treatment at an irradiance level of 0.3 mW/cm2, and while the intensity of radiation delivered decreases with increasing corneal depth, there appears to be a risk for endothelial damage in thinner corneas where the endothelium is closer to the surface," said Dr. Seiler.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.